Overview

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Male
Summary
Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborator:
Sanofi
Treatments:
Alfuzosin
Criteria
Inclusion Criteria:

- Males 45-75 years of age

- Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED

- Men with steady partner and who agree to attempt sex once a week.

Exclusion Criteria:

- Prostate cancer

- Prostatitis

- Penile disease

- Cardiac co-morbidity

- Pre-existing co-morbid conditions

- History of sensitivity to the drug or similar drugs

- Enrollment in another clinical trial

- Impaired hepatic function

- Impaired renal function

- Mental conditions rendering subject unable to understand the study

- Subjects not likely to comply with protocol